Patients in the UK and Singapore are set to gain earlier access to cutting-edge medical innovations following the launch of a new regulatory innovation corridor between the two countries. This first-of-its-kind collaboration brings together the UK’s MHRA and Singapore’s Health Sciences Authority (HSA) to accelerate the development and approval of the most promising healthcare technologies, including advanced diagnostics.
With Flagship Pioneering as the inaugural industry partner, the corridor offers diagnostics and life sciences companies a coordinated regulatory pathway that enables simultaneous engagement with both regulators. Developers can seek early, informal joint advice, allowing them to plan regulatory strategies more effectively, design stronger clinical studies, avoid duplication across jurisdictions and reduce time to market.
The initiative focuses on high-impact areas such as cancer, neurodegenerative diseases, obesity, rare conditions and next-generation diagnostics, while maintaining rigorous standards for safety and performance. Beyond accelerating patient access, the partnership supports joint horizon scanning for emerging technologies and fosters shared learning on regulatory approaches, strengthening the UK and Singapore’s positions as global life science hubs.
The corridor builds on longstanding UK–Singapore collaboration and aligns with national priorities, including England’s 10-Year Health Plan and Singapore’s Healthier SG programme. Joint work on AI in healthcare, through the HealthAI Global Regulatory Network, will further support innovation in digital and data-driven diagnostics.
